Axsome Therapeutics Inc.

53.12+1.33+2.57%Vol 273.26K1Y Perf -31.51%
Jul 27th, 2021 14:45 DELAYED
BID53.12 ASK53.31
Open51.38 Previous Close51.79
Pre-Market- After-Market-
 - -%  - -
Target Price
138.82 
Analyst Rating
Strong Buy 1.00
Potential %
161.53 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Market Cap2.00B 
Earnings Rating
Buy
Price Range Ratio 52W %
7.68 
Earnings Date
9th Aug 2021

Today's Price Range

50.2553.13

52W Range

50.0590.00

5 Year PE Ratio Range

-17.60-4.50

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-6.45%
1 Month
-29.54%
3 Months
-14.24%
6 Months
-25.13%
1 Year
-31.51%
3 Years
1 891.92%
5 Years
549.00%
10 Years
-

TickerPriceChg.Chg.%
AXSM53.121.33002.57
AAPL146.63-2.3600-1.58
GOOG2 729.37-63.5200-2.27
MSFT285.56-3.4900-1.21
XOM57.68-0.8000-1.37
WFC45.080.07000.16
JNJ172.200.33000.19
FB366.68-5.7800-1.55
GE13.100.18001.39
JPM151.63-0.0200-0.01
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.83-0.786.02
Q04 2020-0.73-0.78-6.85
Q03 2020-0.58-0.580.00
Q02 2020-0.54-0.499.26
Q01 2020-0.60-0.88-46.67
Q04 2019-0.51-0.71-39.22
Q03 2019-0.41-0.56-36.59
Q02 2019-0.31-0.41-32.26
Earnings Per EndEstimateRevision %Trend
6/2021 QR-0.886.38Positive
9/2021 QR-1.063.64Positive
12/2021 FY-3.741.84Positive
12/2022 FY-2.19-20.33Negative
Next Report Date9th Aug 2021
Estimated EPS Next Report-0.88
Estimates Count7
EPS Growth Next 5 Years %-
Volume Overview
Volume273.26K
Shares Outstanding37.57M
Trades Count4.62K
Dollar Volume20.42M
Avg. Volume347.12K
Avg. Weekly Volume292.29K
Avg. Monthly Volume353.53K
Avg. Quarterly Volume362.89K

Axsome Therapeutics Inc. (NASDAQ: AXSM) stock closed at 51.79 per share at the end of the most recent trading day (a -3.52% change compared to the prior day closing price) with a volume of 342.43K shares and market capitalization of 2.00B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 53 people. Axsome Therapeutics Inc. CEO is Herriot Tabuteau.

The one-year performance of Axsome Therapeutics Inc. stock is -31.51%, while year-to-date (YTD) performance is -36.43%. AXSM stock has a five-year performance of 549%. Its 52-week range is between 50.05 and 90, which gives AXSM stock a 52-week price range ratio of 7.68%

Axsome Therapeutics Inc. currently has a PE ratio of -20.10, a price-to-book (PB) ratio of 20.94, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -52.84%, a ROC of -61.78% and a ROE of -75.97%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Axsome Therapeutics Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.88 for the next earnings report. Axsome Therapeutics Inc.’s next earnings report date is 09th Aug 2021.

The consensus rating of Wall Street analysts for Axsome Therapeutics Inc. is Strong Buy (1), with a target price of $138.82, which is +161.53% compared to the current price. The earnings rating for Axsome Therapeutics Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Axsome Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Axsome Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 16.72, ATR14 : 2.95, CCI20 : -116.70, Chaikin Money Flow : -0.29, MACD : -3.16, Money Flow Index : 35.41, ROC : -20.09, RSI : 30.16, STOCH (14,3) : 5.66, STOCH RSI : 0.14, UO : 37.81, Williams %R : -94.34), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Axsome Therapeutics Inc. in the last 12-months were: Mark Coleman (Buy at a value of $29 075)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (100.00 %)
8 (100.00 %)
7 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Axsome Therapeutics Inc.

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and others.

CEO: Herriot Tabuteau

Telephone: +1 212 332-3241

Address: 200 Broadway, New York 10038, NY, US

Number of employees: 53

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

80%20%

Bearish Bullish

54%46%

Bearish Bullish

59%41%

News

Stocktwits